Secondary Logo

Journal Logo


Genes for RNA-binding proteins involved in neural-specific functions and diseases are downregulated in Rubinstein-Taybi iNeurons

Larizza, Lidia MD,*; Calzari, Luciano; Alari, Valentina; Russo, Silvia

Author Information
Neural Regeneration Research: January 2022 - Volume 17 - Issue 1 - p 5-14
doi: 10.4103/1673-5374.314286
  • Open


Induced Pluripotent Stem Cell-Neuronal Model of Rubinstein-Taybi: a Tool for Mechanistic Insights into Intellectual Disability

Rubinstein-Taybi syndrome (RSTS. MIM #180849, #613864) is a rare multisystem developmental disorder characterized by moderate to severe intellectual disability often accompanied by behavior disorder (Ajmone et al., 2018), facial dysmorphisms, including microcephaly and prominent beaked nose, small stature, skeletal dysplasia, multiorgan malformations, and cancer predisposition (Hennekam, 2006). It is caused by monoallelic pathogenic variants in either CREBBP (MIM #600140) or EP300 (MIM #602700) genes encoding the CBP and p300 lysine (K) acetyltransferases (HATs or KATs) (Sheikh and Akhtar, 2019) with a key role in development and adult life of the nervous system (Valor et al., 2011). RSTS belongs to the expanding group of disorders of the epigenetic machinery (Fahrner and Bjornsson, 2019; Larizza and Finelli, 2019) most of which share intellectual disability. To obtain insights into the molecular basis of cognitive impairment, representing the most devastating clinical sign of RSTS, we established the in vitro induced pluripotent stem cell (iPSC) neuronal model from peripheral blood of CREBBP and EP300-mutated patients displaying different levels of cognitive defects (Alari et al., 2018a, b, 2019). Morpho-functional characterization of patients’ versus controls’ neuronal cultures appointed altered morphology of differentiating neurons and reduced excitability of post-mitotic neurons as potential RSTS biomarkers (Alari et al., 2018b). We then compared by means of RNASeq the differentially expressed genes marking the transition from iPSC neural progenitors to cortical neurons of a set of RSTS patients versus a set of healthy controls (Calzari et al., 2020). Consistent with the morphological and electrophysiological data, transcriptome analysis of RSTS iPSC-derived neurons (iNeurons) revealed a defective and altered neuroprogenitor to neuron transcriptional program. In brief, transcriptional regulation is weaker in RSTS neurons due to a lower number of modulated genes with respect to control neurons and is subverted by improper upregulation of genes involved in neural migration and axonal targeting and by downregulation of RNA and DNA metabolic genes (Calzari et al., 2020). The latter signature of the RSTS transcriptome is compounded by a large array of downregulated genes (DRGs) associated with the macro-categories of RNA processing (GO Term Cluster 7), Ribonucleoprotein complex biogenesis (G4), telomere maintenance (G2), and DNA metabolic processes (G6) as detailed and discussed in Calzari et al. (2020).

We herein overview the sets of RSTS neuron-specific DRGs (Calzari et al., 2020), associated with the complementary GO term clusters of RNA processing and Ribonucleoprotein complex biogenesis, that encode RNA-binding proteins (RBPs) involved in alternative splicing and ribonucleoprotein biogenesis. The medical relevance of several DRGs pertaining to top and extended DRGs lists (Calzari et al., 2020) is underlined by their links to associated neurological/neurodevelopmental disorders. The high number of DRGs specific of RSTS neurons does not consent analytic comments, but their functional coherence allows discussion of the general network in the framework of the molecular and clinical evidences provided by studies on other human and mouse neuronal systems. Notably, our data give a clue to the recognized connection between chromatin modifiers and alternative splicing (Luco et al., 2010, 2011; Li and Fu, 2019). Indeed, the set of RBPs acting in pre-mRNA splicing and processing predicted at a reduced amount in CREBBP/EP300 mutated iNeurons is consistent with the impact of CBP/p300 depletion on the regulation of cryptic splice sites (Blazquez et al., 2018; Boehm et al., 2018) and the highly conserved neuron-specific microexons splicing program (Gonatopoulos-Pournatzis et al., 2018; Lopez Soto et al., 2019). Functional links between the epitranscriptome and the RBP-ome are also highlighted by DRGs for RBPs involved in ribonucloprotein biogenesis as some of these proteins perform as “dual” players. The overall signature of DRGs in RSTS iNeurons informs on the negative repercussion of defective CBP/p300 on multiple RBPs which cumulative dysfunction contributes to cognitive impairment.

Search Strategy and Selection Criteria

We searched the literature published in the period 2000-2020 using the terms in the Title, Abstract and Keywords on PubMed and retrieved further articles by Pub Med related functions and citation tracking. Due to the fast-growing field of RNA binding proteins we prioritized contemporary literature with the exception of milestones papers. OMIM, Gene Cards, Human Gene Mutation Database, Chromatin databases were relevant tools in our study. The major inclusion criteria were literature on the link between chromatin dysregulation and altered RNA binding proteins assembly and their impact on neuronal functions and neurodevelopmental disorders.

RNA-Binding Proteins

RNA-binding proteins (RBPs) are a large class of > 2000 proteins, which contain RNA binding domains (RBDs) for the purpose of binding target RNAs via specific sequence motifs (Gerstberger et al., 2014b; Corley et al., 2020). They interact with all known classes of coding and non-coding RNAs making up assemblies referred to as RNA-protein complexes (RNPs) (Gerstberger et al., 2014b). The RNPs regulate gene expression at all stages of the mRNA life cycle, encompassing alternative splicing (AS) and nucleocytoplasmic shuttling, mRNA localization, stability, and translation (Hentze et al., 2018). In the nervous system RNPs regulate the spatio-temporal gene expression to adjust neuronal functions according to the ever-changing environment, and to insure that RBP-select mRNAs are transported to subcellular compartments such as dendrites and axons for localized translation (Thelen and Kye, 2019). AS has emerged as the fundamental mechanism for providing the heterogeneous neurons with the unique repertoire of protein isoforms needed for development of neural cell type-specific properties, synapse specification, and establishment of functional networks (Furlanis and Scheiffele, 2018). It is thus not surprising that mis-regulation of RBPs leads to development of an increasingly recognized number of disorders mostly of neurologic, muscular, and sensory origin (Lukong et al., 2008). About 200 RBPs are recorded in the OMIM database ( as being associated with human diseases, attesting to their key role in post-transcriptional regulation of gene expression.

Many excellent reviews have covered the classification of RBPs, based on the structure and function of their RBDs, binding preferences and target RNAs, high conservation across species, and ubiquitous or tissue-specific expression (Gerstberger et al., 2014a, b; Neelamraju et al., 2015). The technical approaches for studying system-wide protein-RNA interactions and the transcriptomic and computational methods for tackling RBPs interaction networks have been expertly reviewed (Hentze et al., 2018; Sternburg and Karginov, 2020) as well as the software cataloging or predicting RBPs and their targets (Corley et al., 2020).

As most RBPs are multitasking, there are limitations in their assemblage by function. However clustering them by class is biased due to the continuous update of RBPs census (Gerstberger et al., 2014a), as the function of at least one-third of RBPs is unknown and the list of “unconventional” RBPs, lacking discernible RBDs, is growing over time (Hentze et al., 2018). Given that members of different RBPs families act in concert on specific cell processes, we grouped the univocal DRGs of RSTS iNeurons based on their main shared function to underscore weakened gene networks at the root of RSTS neurodevelopmental disorder.

Genes for RNA Binding Proteins Are Downregulated during Differentiation of Rubinstein-Taybi Induced Pluripotent Stem Cell-Neurons

RSTS-univocal top DRGs include about 30 members of diverse RBP families. A similar collapse of the post-transcriptional regulation machinery has been observed in the transcriptome of iNeurons from patients with autism spectrum disorders (DeRosa et al., 2018) and cardiomyocytes from patients with Cornelia de Lange, an intellectual disability syndrome often presenting with autistic traits (Mills et al., 2018). The shared signature of distinct neurodevelopmental disorders may originate by the failure to safeguard the highly dedicated post-transcriptional regulation program during differentiation to neurons and cardiomyocytes when transcription hubs such as the autism and the cohesin genes, forming critical interactions in the 3D genome with the splicing regulation network, are damaged. As regards RSTS, it is predictable that a defect of either CBP or p300 multifunctional transcriptional coactivators, that acetylate a multitude of diverse signaling effectors and enhancer-associated regulators (Weinert et al., 2018) might subvert the RBP-ome profile, especially of proteins involved in RNA AS and processing, a strictly regulated process in neuronal cells (Furlanis and Scheiffele, 2018). Furthermore, functional cross-link between chromatin regulation and alternative splicing has been documented in a range of organisms favoring an integrated model of the role of chromatin and histone modifications for alternative splice site selection and other RNA processing events (Luco et al., 2010, 2011). Splicing of very short exons (3–27 nt), a highly conserved program of AS in neural cells, has been revealed to be highly relevant in shaping protein-protein interactions associated with brain-specific functions (Irimia et al., 2014) and has been linked to autism-spectrum and psychiatric disorders by genome-wide CRISPR-Cas9 interrogation of splicing networks (Gonatopoulos-Pournatzis et al., 2018). Remarkably, these screens showed that several genes impact the main SRRM4 splicing regulator of the activity-dependent neuronal microexons, and act at multiple regulatory levels, including RNA processing, chromatin regulation, and protein turnover (Gonatopoulos-Pournatzis and Blencowe, 2020). CBP/p300 are the main chromatin regulators impacting this network, as demonstrated by reduced SRRM4 levels upon their depletion in mouse neuronal cells (Gonatopoulos-Pournatzis et al., 2018).

Our overview is focused on DRGs sorted to the most expanded Go term Clusters “RNA processing” and “Ribonucleoprotein complex biogenesis” with several “multifunctional” DRGs acting in both processes (Calzari et al., 2020). Top DRGs (padj cutoff < 1 × 10–3) and functionally linked, though less significant, DRGs are discussed.

Downregulated RNA Binding Protein Gene Families Involved in Alternative Splicing

Several univocal RSTS DRGs encode members of RBPs families which act in a synergistic/antagonistic way in AS regulation. Some encode components of the spliceosome, a dynamic multi-megaDalton ribonucleoprotein (RNP) complex that executes precursor messenger RNA (pre-mRNA) splicing by recognition of core sequence elements (van der Feltz et al., 2012), while others encode trans-acting regulators which recognize by their RBDs the target RNAs. The spliceosome catalyzes the removal of introns and ligation of exons: splicing choices are largely achieved by cis-acting elements referred to as exonic enhancers and intronic silencers that recruit RBPs for binding (Hentze et al., 2018). The contribution of RBPs to AS is to regulate the access of the core splicing machinery, which is strongly dependent on the cell-specific RBP-ome and the position (relative to the regulated exon) of the RNA binding motif (Furlanis and Scheiffele, 2018). AS shapes the entire life cycle of a neuron from early differentiation to axonal guidance and synapse formation and signaling till maintenance of neural circuit function response to a dynamic environment (Furlanis and Scheiffele, 2018; Lipscombe and Lopez Soto, 2019). Over 90% of human pre-mRNAs are subject to AS (Wang et al., 2008) and the splicing decisions are regulated in a cell type- and cell state-dependent manner. In the nervous system the capacity of multi-exon genes to generate a huge number of splice variants to diversify protein isoforms across brain regions and developmental stages (Furlanis and Scheiffele, 2018) and to transport selected transcripts within neurons’ subcellular compartments for local translation has proven indispensable for development, synaptic plasticity and long term memory (Bramham and Wells, 2007). Indeed, the magnitude of AS has remarkably increased in organisms with more complex nervous systems, such as mammals (Furlanis and Scheiffele, 2018). A specific and highly conserved program for recognizing and splicing microexons has evolved in the mammalian nervous system and its perturbation has been linked to autism and cognitive dysfunction syndromes (Irimia et al., 2014; Gonatopoulos-Pournatzis et al., 2018). AS also produces mRNA variants that are substrates for nonsense-mediated mRNA decay, which serves to eliminate aberrant mRNA transcripts with premature termination codons and to finely regulate post-transcriptional regulation (Lykke-Andersen and Jensen, 2015). Missplicing events leading to exon skipping or intron retention (Wang et al., 2008; Das et al., 2019) have severe repercussions on neuronal functions, as indicated by the growing number of diseases of the nervous system characterized by aberrant splicing, either driven by mutations that disrupt splicing directly by interfering with cis-acting elements and trans-acting splicing factors or indirectly by sequestering RNPs to visible membraneless nuclear or cytoplasmic compartments with an arrested translation of their scaffold RNA (Lipscombe and Lopez Soto, 2019). Pervasive transcriptome-wide isoform-level deregulation in the human brain has been reported to be associated with autism spectrum disorders, schizophrenia, and bipolar disorders (Gandal et al., 2018).

Additional Table 1 outlines the DRGs in RSTS iNeurons encoding RBPs members of heterogeneous nuclear ribonucleoproteins (hnRNPs) family, Small Nuclear Ribonucleoprotein Polypeptides (snRNPs), and Serine and Arginine splicing factors (SRSF), acting in pre-mRNA AS either cooperatively or in competition for overlapping binding sites.

Additional Table 1 RNA-binding proteins genes mainly involved in alternative splicing downregulated in Rubinstein-Taybi syndrome induced pluripotent stem cell neurons


hnRNPs, referred to as “mRNA clothes” as they bind nascent transcripts produced by RNA polymerase II (heterogeneous nuclear RNA hnRNAs/pre-mRNA) and supervise their maturation into messenger RNAs (mRNA), stabilization, transport and translation, have been intensively investigated for their relative abundance (> 50% of RBPs), multifunctional regulatory roles and dysfunction in neurodegenerative/neurodevelopmental disorders (Chaudhury et al., 2010; Han et al., 2010; Geuens et al., 2016). hnRNPs are ubiquitously expressed and their main function is to control cryptic exon inclusion and inhibit cryptic polyadenylation sites safeguarding the integrity of the transcriptome (Das et al., 2019).

The human genome contains about 40 hnRNP genes comprising distinct subfamilies originating via duplication events, designated alphabetically from hnRNPA1 to hnRNPU. All contain one or more modular RBDs out of the ~600 structurally distinct ones which have been described (Gerstberger et al., 2014a; Corley et al., 2020). The most represented RBDs include RNA Recognition Motifs (RRM), quasi-RRM (qRRM), K-Homology RBD and/or RGG boxes consisting of Arg-Gly-Gly repeats with interspersed aromatic amino acids (Phe/Tyr) and Gly-, Arg-, Lys-, Pro-rich auxiliary domains for homologous and heterologous interaction with RNA or proteins (Han et al., 2010). These latter motifs are typical of C-terminus intrinsically disordered regions (IDRs) which, despite their lack of structure, act as RBDs driving the majority of protein-RNA interactions in the cell and are enriched among the hubs in protein interaction networks (Neelamraju et al., 2015; Hentze et al., 2018).

Each hnRNP family member differs in the number and orientation of its subunits whose modularity contributes to the combinatorial nature by which they associate with different RNA targets (Levengood and Tolbert, 2019). Most hnRNPs have a nuclear localization signal (NLS) and are predominantly present in the nucleus during steady-state, appearing at electron microscopy in large nucleosome-like complexes referred to as “ribonucleosomes”, a term pointing to their main function of packaging pre-mRNAs (Chaudhury et al., 2010). Upon post-translational stimulation or recruitment of other hnRNPs they shuttle to the cytosol where often undergo post-translational modifications (acetylation, phosphorylation, methylation, small ubiquitin-like modification) and regulate mRNA localization, stability, and the efficiency with which specific mRNAs are translated (Han et al., 2010; Geuens et al., 2016). Though hnRNPs are clustered in one family because of some commonalities and shared functions, their structural and functional divergence is increasingly recognized making their distinction from RBPs questionable (Han et al., 2010). In the nervous system where highly polarized neurons, with axons as long as one meter, are highly dependent on local translation and a transcriptome of > 2500 mRNAs is present at synaptic regions (Cajigas et al., 2012), hnRNPs are crucial for transporting the stabilized mRNAs one by one along the axonemal cytoskeleton to the subcellular hubs of protein translation. Deregulation of hnRNPs dosage and dynamics due to persistent cellular stress or mutations disrupting neuronal ribostasis and proteostasis is at the root of several neurodegenerative and neurodevelopmental disorders (Nussbacher et al., 2019).

Additional Table 1 shows the major hnRNP A1, A2B1, D, G (RBMX), H1/H2, and the minor MAGOHB and PABPC1 family members downregulated in RSTS neurons. Their structural domain organization is shown in Figure 1 and summarized with their functions, and their link to constitutional diseases in Additional Table 2.

Figure 1:
Domain organization of hnRNPs A1, A2B1, D, G and H1/H2.RNA binding domains (RBDs) include: RNA recognition motifs (RRM) and quasi RNA recognizing motifs (qRRM), RGG boxes (arginine-glycine-glycine repeats with interspersed Phenylalanine/Tyrosine). The amino acid sequence of A2B1 is identical to that of A2 except that 12 aminoacids are inserted near its N-terminal. G-rich, Y-rich: Glycine-tyrosine-rich; G-, Y-, R-rich: glycine-tyrosine, arginine-rich domains; NLS: nuclear localization signal; NTD: nascent transcript domain; PrLd: prion-like domains; SRGP-rich: serine, arginine, glycine, proline-rich region in the low complexity region of hnRNPG.
Additional Table 2 hnRNPs downregulated in Rubinstein-Taybi syndrome neurons, acting in the regulation of alternative splicing: structural motifs, functions and link to disease


A1 is the prototypical and best-known member of the hnRNP family. Composed of 2 RRM domains, close to one another and similar in size, and 1 C-ter IDR with a RGG box, it is structurally similar to A2B1 (2 RRM and 1 C-ter IDR with an RGG box) (Figure 1 and Additional Table 2). The RRMs are the primary RNA binding surface, whereas the IDRs mediate protein-protein interactions. The presence within the G-,Y-rich IDRs of mammalian-specific alternative exons mediates the formation of tyrosine-dependent multi-hnRNP assemblies that globally regulate splicing patterns, highlighting a mechanism that has expanded the AS regulatory capacity of mammalian cells (Gueroussov et al., 2017). On the other hand, due to the repeats of non-polar (Gly) and aromatic amino acids (Phe/Tyr), the IDRs of these hnRNPs are “prion-like domains” (PrLDs), i.e. protein conformers that self-replicate by templating the folding of soluble proteins with the same amino acid sequence (Harrison and Shorter, 2017; Levengood and Tolbert, 2019; Liu and Shi, 2020). PrLDs enable RBPs to undergo liquid-liquid phase separation, a process underlying the biogenesis of various membraneless organelles, such as Cajal bodies in the nucleus and stress granules in the cytoplasm, which are highly dynamic and assemble and disassemble according to the local environment. Inappropriate transitions due to loss of neuronal homeostasis or mutation render these proteins prone to misfolding and aggregation around the mRNA scaffolds, thus reducing the pool of functional protein, and interfering with its normal function, outlining a common pathway to neurodegeneration (Harrison and Shorter, 2017; Picchiarelli and Dupuis, 2020).

hnRNPA1 and hnRNA1B2 are multitasking proteins with a major role in the regulation of AS and splice-site selection, often promoting exon skipping (Jean-Philippe et al., 2013; Liu and Shi, 2020). They are essential for the maintenance of transcriptome integrity by protecting thousands of endogenous pre-mRNA transcripts with highly complex sequences against mis-splicing (Das et al., 2019). Both have a role in nucleocytoplasmic transport, stability, and degradation of mature mRNA transcripts, mRNA translation, telomere biogenesis, and length maintenance (Han et al., 2010; Shishkin et al., 2019). A1 also participates in microRNA processing. A1 and A2B1 are among the most abundantly expressed proteins in the cells, only rivaling histones, and form “ribonucleosomes” with many other different hnRNPs. In the cytoplasm, they are involved in RNP granules assembly whose packaging in conditions of cellular stress or mutation leads to the arrest of mRNA translation and accelerated fibrillization of the altered protein (Picchiarelli and Dupuis, 2020). Differently from hnRNPA1, hnRNPA2B1 plays a crucial role in mRNA trafficking in neurons and oligodendrocytes and is important for the localization of transcripts containing an A2 response element (Liu and Shi, 2020). It is a reader of N6-methyladenosine (m6A), the most abundant internal modification of mRNA, and binds the nuclear modified transcripts to elicit their alternative splicing and processing (Alarcon et al., 2015). A2B1 has been recognized as an innate sensor of DNA virus infection in the nucleus, able to elicit and amplify type I interferons responses, also promoting m6A modifications (Wang et al., 2019; Additional Table 2).

Whole exome sequencing and linkage analysis detected mutations in the C-ter PrLDs of hnRNPA1 and hnRNPA2 (the shorter hnRNPA2B1 isoform) in families affected by a rare multisystem proteinopathy formerly known as Inclusion Body Myopathy with Paget’s bone disease, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS) (Benatar et al., 2013; Kim et al., 2013). Additional hnRNPA1 and hnRNPA2 mutations were detected in patients with sporadic and familial ALS, though their prevalence in ALS is unknown (Harrison and Shorter, 2017). The pathogenic role of these hnRNPs may go beyond the rare cases of germinal mutations as attested by their widespread colocalization in stress granules with other frequently mutated ALS proteins (Picchiarelli and Dupuis, 2020). It has been claimed that RBP homeostasis should be considered globally and that consequences on multiple RBPs could be expected upon mutation of one single member. Based on accumulation and colocalization with other mutated RBPs, both A1 and A2B1 could be involved in several muscular and neurological diseases (Picchiarelli and Dupuis, 2020; Additional Table 2).

hnRNPD, alias AUF1 (AU-rich element binding factor 1) comprises 4 isoforms generated by AS constituted by two non-identical RRM and a C-ter IDR with several RGG motifs which hosts a nonclassic nuclear localization signal (Figure 1). The RRMs serve to form complexes with AU-rich elements in the 3′-untranslated regions of many proto-oncogenes, cytokines, and circadian clock gene mRNAs: as a result, hnRNPD plays a defined role in destabilizing mRNAs, often associated with accelerated mRNA decay (White et al., 2017). Besides binding in a specific manner to single-stranded telomeric DNA (Shishkin et al., 2019), hnRNPD binds chromatin DNA functioning like a transcription factor. It has been recognized as a new player in DNA double-strand break repair via homologous recombination, able to localize at the sites of damage and to act in the DNA-end resection process (Alfano et al., 2019; Additional Table 2). hnRNPD is comprised with its hnRNPDL paralog within the commonly deleted region of the 4q21 microdeletion syndrome (Additional Table 2) characterized by severe psychomotor retardation, marked growth restriction, distinctive facial features and absent or severely delayed speech (Bonnet et al., 2010).

hnRNPG, alias RBMX (RNA Binding Motif Protein X-linked), contains an N-terminal RRM, a large low complexity Ser-Arg-Gly-Pro-rich region, and a C-terminal RBD (Figure 1). The IDR region which self assembles into large particles in vitro comprises the nascent transcripts targeting domain, involved in the recognition of an RNA motif exposed by m6A modification (Liu et al., 2017). The hnRNPG protein ubiquitously controls pre-mRNA AS site selection and can either activate or suppress exon inclusion of several neurological disease-associated genes (Wang et al., 2011). Its role in neural development is attested by the association of a C-terminal truncating mutation to a human intellectual disability syndrome (MIM #300238) (Shashi et al., 2015). Besides being involved in DNA damage repair, chromatid cohesion, and transcriptional regulation, hnRNPG is an m6A reader, using its IDR to bind the exposed modified purine rich-motif, contributing to the AS regulation of m6A modified mRNA transcripts (Liu et al., 2017; Additional Table 2).

hnRNPH1 and hnRNPH2, also named hnRNP and hnRNPH’, sharing 96% homology and encoded by the HNRNPH1 and HNRNPH2 genes, possess 3 non-conserved highly homologous RNA Recognition Motifs (qRRM), one glycine/tyrosine/arginine-rich domain-containing a nuclear localization signal (NLS), and one glycine/tyrosine-rich domain (Figure 1). The best-known function of hnRNPH1/2 is the control of AS: both are repressors of neurogenesis, in part by preventing the expression of the pro-differentiation TRF2-s (Telomere-Repeat Factor 2-short isoform), though H1 appeared to have a stronger splicing effect (Grammatikakis et al., 2016). A role for H1 in the control of human stem cell fate has been highlighted by demonstrating that its reduced expression modifies the mutually exclusive isoforms of T-cell Factor 3 transcription regulator during differentiation of pluripotent human ESCs (Yamazaki et al., 2018) (Additional Table 2). A study reported on the role of hnRNPH sequestered together with other hnRNPs in toxic RNA foci in the spinal cord of amyotrophic lateral sclerosis/frontotemporal dementia patients (Cooper-Knock et al., 2015).

Monoallelic pathogenic variants, believed to act by gain-of-function mechanism, were first identified in HNRNPH2 by whole exome sequencing on patients with syndromic intellectual disability (Bain et al., 2016). As all the first mutation carriers were females, the new syndrome (MRXSB, MIM #300986), characterized by intellectual disability, dysmorphic features, feeding problems, and hypotonia, was thought to be potentially lethal in males, but males with features consistent with MRXSB were later reported, together with additional females (Harmsen et al., 2019; Jepsen et al., 2019; Peron et al., 2020; Somashekar et al., 2020; Additional Table 2).

The first pathogenic variant in the paralog autosomal HNRNPH1 gene was reported in a patient whose phenotype partially overlapped that of HNRNPH2-caused syndrome but included unique features (Pilch et al., 2018), a finding confirmed by the description of seven new HNNRPH1-mutated patients (Reichert et al., 2020). It is noteworthy that most variants in both genes affect the glycine/tyrosine/arginine-rich domain containing the nuclear localization signal, between amino acids 194 and 220, with the 205–213 stretch highly conserved and required for nuclear transport, suggesting improper nucleocytoplasmic shuttling of the pathogenic variants. The c.616C > T, pArg206Trp variant is shared by 10/12 HNRNPH2- and 5/8 HRNRPH1- mutated patients reported so far (Figure 2). Further patients need to be characterized to delineate the phenotypic spectrum of this new neurodevelopmental syndrome and assess its common/unique features in comparison with the H2-caused neurodevelopmental disorder. Notably, both disorders share developmental and speech delay, a few dysmorphic features, feeding problems, and skeletal issues with RSTS. However, with the limitation of the small number of patients, HNRNPH1-mutated patients share additional H1-unique features with RSTS, such as MRI brain anomalies, congenital microcephaly, palate abnormalities, distinctive dysmorphisms such as long prominent nose with hypoplastic alae nasi and low hanging columella, micrognathia and congenital malformations of ocular and urogenital systems (Pilch et al., 2018; Reichert et al., 2020). This clinical resemblance may be accounted for by the finding that HRNRPH1, unlike HNRNPH2, is downregulated in RSTS iNeurons (Additional Table 1). A likened signature of distinct neurodevelopmental disorders may result from shared or interconnected neural gene networks and targetomes of different downregulated brain-specific proteins.

Figure 2:
Pathogenic variants of HNRNPH2 and HNRNPH1 genes causing MRXB (Mental Retardation X, Bain type) syndrome and the related H1-caused intellectual disability syndrome are clustered at the most conserved amino acids from 205 to 213 of the nuclear localization signal (NLS) within the glycine/tyrosine/arginine-rich (GYR) region.The number of red dots to the left of each variant indicates the number of affected carriers identified so far.

MAGOHB (Magoh Homolog B) (Additional Table 1), is one of the core components of the mRNA splicing-dependent exon junction complex (EJC) which is deposited on nascent spliced transcripts at a fixed position (~24 nt) upstream of splice junctions without specific RNA binding but by means of protein-protein interactions (Bono et al., 2006). MAGOHB, together with its ortholog MAGOH plays a redundant, but essential role in the splicing complex and nonsense-mediated mRNA decay, cleavage of growing transcripts in the termination regions, and transport of mature transcripts to cytoplasm (Singh et al., 2013). Several studies have showed that EJC components are essential for brain development and adult brain functioning. Heterozygous mice generated by a ubiquitous conditional deletion of magoh develop microcephaly (McMahon et al., 2014). It is worth noting that MAGOHB is a top DRG in RSTS neurons (Additional Table 1) and microcephaly is a universal feature of RSTS patients (Hennekam, 2006). Recent studies have confirmed that all EJC protein components, in concert with EJC auxiliary or “peripheral” proteins, impact splicing by suppressing the use of nearby cryptic splice sites (Boehm et al., 2018) and partially spliced transcripts generated by “recursive splicing” (Blazquez et al., 2018). One of the ECJ peripheral proteins, a component of the PASP complex with RNPS1 and SAP18, is the splicing activator Pinin, downregulated in RSTS iNeurons (Additional Table 1). Mechanisms regulating splicing of neuron-specific microexons lead back to ECJ via the combinatorial capacity of ECJ and its peripheral proteins SRSF11 and RNPS1 to interact with the SRRM4 protein, top activator of microexons splicing program (Gonatopoulos-Pournatzis et al., 2018).

PABPC1 (PAPB1) and PAPBC1L are hnRNPs containing four RNA-recognition motifs (Additional Table 2). The first two, RRM1 and RRM2, bind both α-importin and the poly(A) tail of processed mRNA, required for poly(A) shortening which is the first step of mRNA decay and translation initiation. This prevents mRNA from going back into the nucleus. PABPC1 and PAPBC1L are also involved in RNA transport and RNA surveillance pathways (Additional Table 2).


Another set of RSTS iNeurons DRGs includes the Small Nuclear Ribonucleoproteins polypeptides D1, D2, D3, F, G (Additional Table 1), i.e. five of the seven “sm” proteins which make up the structural core shared by the four major RNA-protein assemblies termed uridine-rich U1, U2, U4/U5, U6, small nuclear ribonucleoprotein particles of the eukaryotic pre-mRNA splicing machinery. “Sm” proteins, sharing two evolutionary conserved sequence motifs involved in “sm” protein-protein interactions (Hermann et al., 1995) are critical to the assembly, transport, and integrity of the U snRNPs. It is to be noted that, in particular, members of the spliceosomal U2 snRNPs are, like EJC, proximal partners of the RNPS1 and SRSF11 proteins, co-activators of microexons splicing. For snRNPs too, the RNA-protein interactions are not mediated by RBDs as the spliceosome functional assemblage is driven by the shape and biochemical complementarity between the small nuclear RNAs folded into 3D structures and protein partners (van der Feltz et al., 2012; Hentze et al., 2018). The downregulated snRNP40 and snRNP48 (Additional Table 1) are structural components of U5 and U11/U12 snRNPs, respectively. snRNA-activating protein complex 1 (Additional Table 1) is a transcription factor that, by binding to the proximal sequence element of RNA polymerase II and III promoters, directs both RNA polymerases gene transcription.

Splicing Factors

RSTS neurons DRGs include SRSF3 and SRSF7, two paralogous gene members of the SR-rich family of pre-mRNA splicing factors, which are part of the spliceosome (van der Feltz et al., 2012; Hentze et al., 2018) (Additional Table 1). These RBPs contain an N-terminal RRM for binding RNA and a C-terminal RS domain of consecutive Arginine and Serine dipeptides which facilitates interaction between different splicing factors and other proteins, such as the splicing coactivator Pinin (Additional Table 1), a peripheral EJC protein with an RS domain (Boehm et al., 2018). Besides promoting exon inclusion during AS, they are also involved in mRNA export from the nucleus and in translation.

MBNL3 (Additional Table 1) is a member of the muscleblind family, which mediates pre-mRNA AS regulation as an activator or repressor on specific pre-mRNA targets in antagonism with the splicing activity of the CELF (CUG Elav Family binding protein proteins (Wang et al., 2015). It contains the Zinc knuckle motif (ss-RNA binding zinc finger-CCHC) (Gerstberger et al., 2014b), that can inhibit terminal muscle differentiation (Brinegar and Cooper, 2016) and plays a role in Myotonic Dystrophy pathophysiology.

Downregulated RNA-Binding Proteins Involved in mRNA Transport

Along with several hnRNP family genes, DRGs of RSTS neurons acting in mRNA transport include NUP35 for a nucleoporin which functions as a component of the nuclear pore complex and the transmembrane NDCI nucleoporin (Additional Table 3). NUTF2 encodes a cytosolic factor that facilitates protein transport into the nucleus and is required for nuclear import of the small Ras-like GTPase which is involved in numerous cellular processes. ENY2 (Transcription and Export Complex 2 subunit 2) encodes a multifunctional protein involved in the coupling of transcription with mRNA export. ENY2 associates with a multiprotein complex that remodels chromatin and mediates histone acetylation and deubiquitination and a multiprotein complex implicated in the export of mRNA to the cytoplasm through the nuclear pore, connecting gene expression from transcription to translation (Additional Table 3).

Additional Table 3 Genes for RNA binding proteins downregulated in Rubinstein-Taybi syndrome induced pluripotent stem cell neurons involved in mRNA transport and translation initiation

Impaired Ribosome Biogenesis in Rubinstein-Taybi Induced Pluripotent Stem Cell-Neurons

Additional Table 4 lists the genes for nucleolar/ribosomal proteins downregulated in RSTS neurons. Ribosomes, the incredibly complex macromolecular machine catalyzing protein synthesis, are composed of four heavily chemically modified non-coding rRNA (5S, 5,8S, 18S, 25/28S) and ~80 structurally distinct proteins. Biogenesis of ribosomes is a process that needs to couple translation of ribosomal proteins to transcription, processing, and modification of rRNAs, and then governs the assemblage of > 200 components (Ojha et al., 2020). Most of the 169 annotated ribosomal proteins lack conventional RBDs and bind directly to rRNA by shape complementarity, operating as RNA-protein complexes, similarly to the vast majority of non-coding RNAs (snRNPs, snoRNPs, telomerase, microRNAs, and lncRNAs) (Hentze et al., 2018).

Additional Table 4 Genes for pre-rRNA processing and ribosome biogenesis downregulated in Rubinstein-Taybi syndrome induced pluripotent stem cell neurons

Prominent for rRNA processing are the small nucleolar RNAs (snoRNAs), a large group of non-coding RNAs which also assist in ribosome assembly, mostly localized in the nucleolus, the site of rRNA biogenesis. Nucleolar proteins and snoRNAs form snoRNPs that mediate post-transcriptional modifications, pseudouridylation, methylation, and cleavage needed for rRNA maturation (Boisvert et al., 2007), contributing to the translational control of gene expression (Sloan et al., 2017). The two key snoRNP complexes are box C/D protein-containing and box H/ACA protein-containing-RNPs (Watkins and Bohnsack, 2012). Box C/D RNPs catalyze site-specific 2′-O-methylation of rRNAs, snRNAs, and tRNAs in an RNA-guided manner: the associated core proteins, together with SNU13 and NOP56 ribonucleoprotein, are the evolutionarily conserved proteins fibrillarin (FBL) and NOP58 (Cervantes et al., 2020), top DRGs in RSTS neurons (Additional Table 4). FBL participates in the first step in processing pre-ribosomal RNA, associated with multiple snRNAs and the U3, U8, and U13 snoRNAs and is the catalytic methyltransferase of the Box C/D snoRNPs mediating the deposition of 2′-O-methylation of ~100 residues of rRNA using RNA-RNA base-pairing of one snRNA to direct target sites (Ojha et al., 2020). FBL is equipped with a ribonuclease activity in its glycine/arginine-rich (GAR) domain, conserved in a small group of RNA interacting proteins, such as GAR1 (Additional Table 4). This domain, interacting with phospholipids in the nucleoli, may allow a phase separation (liquid-liquid phase separation) of rRNA-associated proteins containing IDRs, such as fibrillarin and GAR1, thought to be implicated in processing modifications during ribosome production (Guillen-Chable et al., 2020). NOP58 also associates with box C/D U3 and U8 snoRNAs to control specific pre-ribosomal RNA processing steps (Cervantes et al., 2020). Box H/ACA snoRNPs catalyze the isomerization of uridine to pseudouridine using RNA-RNA base pairing to direct target sites: dyskerin, one of the snoRNPs co-factors (together with GAR1, NHP2, and NOP10) is the catalytic subunit (Ojha et al., 2020). The DKC1-encoded dyskerin pseudouridine synthase1 (Additional Table 4), also plays an active role in telomere maintenance as part of the reverse transcriptase holoenzyme TERT (Additional Table 4), the catalytic core of the ribonucleoprotein complex, having the non-coding TERC RNA as scaffold, that serves as a template for the addition of telomeric repeats to chromosome ends (Roake and Artandi, 2020). Other functions of this highly conserved gene are in nucleo-cytoplasmic shuttling, DNA damage response, and cell adhesion. DKC1 and TERT mutations are associated with X-linked and autosomal Dyskeratosis congenita (MIM # 305000, MIM # 613989), a severe disorder characterized by bone marrow failure, lung fibrosis and increased susceptibility to cancer. Other rRNA processing RBPs are PseudoUridylate Synthase 7 (PUS7), a component of the chaperone system for assembly and trafficking of snoRNPs, enabling post-transcriptional modification to stabilize RNA secondary molecular structure, and methyltransferase like 1 (METTL1), that mediates the formation of N(7)-methylguanine in tRNAs, mRNAs and microRNAs (Additional Table 4). Biallelic mutations in PUS7 are associated with Intellectual Developmental Disorder With Abnormal Behavior, Microcephaly, and Short Stature (IDDABS, MIM # 618342) (de Brouwer et al., 2018).

snoRNA genes are largely found in eukaryotes within the introns of host genes, mainly encoding ribosomal proteins or translation machinery factors, a mechanism allowing coupled synthesis of ribosomal proteins and snoRNAs, which are required for modification of rRNA. Several genes encoding proteins of the small (40 S) or large (60 S) ribosomal subunit are downregulated in RSTS iNeurons (Additional Table 4), including RPS3 and RBL7A whose mRNAs host one and four snoRNAs, respectively (Ojha et al., 2020). While the loss of a single snoRNA that guides RNA modifications is rarely detrimental, the loss of a snoRNA that directs pre-RNA processing (such as U3 snoRNA) is often lethal (Ojha et al., 2020). The snapshot in RSTS iNeurons of DRGs involved in ribosome biogenesis informs on downregulation of rRNA processing that has been shown to significantly alter ribosome biogenesis and function (Sloan et al., 2017).

Crosstalk between Chromatin Regulation and RNA Processing

The commonalities between the epigenome and the epitranscriptome have been highlighted by the similarity between epigenetic modifications involved in chromatin remodeling and RBPs performance as writers, erasers, and readers of the “epitranscriptomic” marks (Hentze et al., 2018), i.e. the diverse modifications not genetically encoded, but “added on the top” of their RNA partners (Mathlin et al., 2020).

Targeted reviews have discussed the histone marks influencing alternative splicing of neural genes and the underlying mechanisms (Luco et al., 2010, 2011; Hentze et al., 2018; Lipscombe and Lopez Soto, 2019). On the other hand, RBPs have revealed a high level of versatility and some have turned out not only to bind RNA, but also DNA. This is the case with hnRNPA1, hnRNPA2B1, and hnRNPD which are able to interact with single-stranded telomeric DNA (Shishkin et al., 2019) meaning that their decreased amount may lead to reduced telomerase activity (Zhang et al., 2006) or impaired DNA double-strand break repair in the case of hnRNPD which also binds chromatin DNA (Alfano et al., 2019). Technological advances able to capture the chromatin-RNA interactome, such as global RNA interaction with DNA sequencing (GRID-Seq), have detected a consistent number of RBPs RNA binding sites mapping to chromatin-related domains such as the chromodomain and the bromodomain (Hentze et al., 2018; Li and Fu, 2019). The landscape of chromatin-associated RNAs is dominated by pre-mRNAs which are mainly co-transcriptionally spliced and processed by secondary modifications, such as m6A, into mature RNAs. Other chromatin–interacting RNAs include several non-coding RNAs, i.e. snRNAs, snoRNAs, lncRNAs and repeat-derived RNAs, the latter playing a central role in heterochromatin formation. All chromatin-associated RNAs may exert regulatory functions, bridging together transcriptional and post-transcriptional regulation of gene expression by various RNA-mediated feedback and feedforward mechanisms. A key class of RNAs, localized at transcriptional hubs in the 3D genome, are enhancer RNAs (eRNAs) (Li and Fu, 2019), which have been shown to bind the transcriptional coactivator CBP/p300 via its catalytic KAT domain leading to an active H3K27 enhancer state and corresponding changes in gene expression (Bose and Berger, 2017). Acetylation of enhancer-associated regulators features a powerful mechanism to prime networking between chromatin histone modifications and post-transcriptional regulation (Li and Fu, 2019). Interestingly, the snapshot of RSTS iNeurons DRGs sorted to the GO Term Clusters of RNA processing and ribonucleoprotein biogenesis highlights “dual specificity” proteins engaged in the crosstalk between RNA processing and chromatin regulation. Significant examples are the nucleolar FBL, NOP58, and RUVBL1 proteins encoded by top DRGs of RSTS iNeurons (Additional Table 4). The essential FBL methyltransferase responsible for rRNA methylation is also involved in nucleoli-restricted methylation of histone H2A in PolI promoters, where the modified 104 glutamine leads to a weakening of the interaction for the histone chaperone FACT (Facilitator of Chromatin Transcription) complex making PolI transit less impeded by nucleosomes (Tessarz et al., 2014). NOP58 is indicated by proteomics as the prominent interactor of BMAL1, the transcriptional regulator of the circadian rhythm clock, that localizes to the nucleolus where it associates with box C/D snoRNPs (Cervantes et al., 2020). BMAL1-null cells show altered nucleolar morphology and impaired pre-RNA processing, suggesting a non-canonical role of BMAL1 in ribosomal RNA regulation (Cervantes et al., 2020). This “unsuspected” role, shared by PER, the product localized to the nucleolus of another circadian rhythm gene, has been attributed to other classic DNA-binding transcription factors and epigenome regulators that have the ability to directly contact RNA, such as the CCCTC-binding factor CTCF, DNA methyltransferases and other Pol II-associated transcription factors localized in the nucleolus (Li and Fu, 2019). RUVBL1 (Additional Table 4), a protein of the ATPases with diverse cellular activities (AAA+) family, has both DNA-dependent ATPase and DNA helicase activities and associates with several multisubunit transcriptional complexes and with protein complexes acting in both ATP-dependent remodeling and histone modification. It is part of a chaperone complex aiding the assemblage of C/D box and H/ACA box snoRNPs and their trafficking from the site of transcription through the Cajal bodies to the nucleolus, despite unrelated RNA structures and protein components (Ojha et al., 2020). An additional dual player is SUV39H1 (Additional Table 4), an evolutionarily-conserved protein containing an N-terminal chromodomain, shown to bind RNA (Velazquez Camacho et al., 2017), and a C-terminal SET domain, specific to histone methyltransferases. It trimethylates lysine 9 of histone H3, which results in transcriptional gene silencing (Johnson et al., 2017) and remains associated with heterochromatin by means of an RNA-mechanism mediated by major satellite repeats RNA (Velazquez Camacho et al., 2017). SUV39H1 plays a central role in the establishment of constitutive heterochromatin at pericentric and telomeric regions; loss of function of the gene disrupts heterochromatin formation and may cause chromosome instability.

Beyond these flags, the nexus between CBP/p300 deficiency and a weakened RBPs network in the transcriptome of RSTS iNeurons relies on the finding of reduced expression of the SR-protein SRRM4, the main regulator of the neural-specific microexons AS program, upon CREBBP/EP300 depletion (Gonatopoulos-Pournatzis et al., 2018). The top DRGs for the EJC core MAGOHB component and five core proteins of the U snRNPs are upstream partners of the SRRM4 network (Figure 3). Microexons splicing was found to be mis-regulated in the post-mortem brain of one-third of autistic subjects (Irimia et al., 2014) and in patients with autistic and psychiatric disorders (Gandal et al., 2018). CREBBP and EP300 are scored in the ASD SFARI database ( in the high confidence category 1 and loss-of-function mutations underlie the neurodevelopmental RSTS syndrome, often characterized by overt ASD or behavior disorder (Ajmone et al., 2018).

Figure 3:
Impact of the acetylation defect in Rubinstein-Taybi syndrome (RSTS) on neural-specific microexons splicing.Top left: monoallelic mutations of either CREBBP or EP300 cause the RSTS neurodevelopmental disorder. Bottom left: RNASeq of RSTS iNeurons shows downregulation of the indicated biological processes (Calzari et al., 2020): a set of functionally related downregulated genes acting in pre-mRNA splicing is outlined. Right: schematic at the DNA and the pre-mRNA level of the main players in the neural-specific microexon splicing of wild type (top) and CREBBP/EP300+/– (bottom) iNeurons. The SRRM4 protein, top regulator of the neural-specific microexons program, has two upstream activators, SRF11 and RNPS1, acting as Exon Junction Complex (EJC) peripheral protein (Boehm et al, 2018; Gonatopoulos et al, 2018). Downregulation in RSTS iNeurons of: i) EJC core component MAGOHB, assembled to EJC as heterodimer with RBM8A (RNA binding motif protein 8A), ii) core proteins of U1, U2, U4/U5, U6 snRNPs and iii) EJC accessory SR protein Pinin predict weakening/disrupture of microexons splicing, consistent with cognitive impairment of RSTS patients.

Concluding Remarks

We surveyed the landscape of downregulated genes for RBPs in the transcriptome of iNeurons modeling the neurodevelopmental Rubinstein-Taybi syndrome, (Calzari et al., 2020) taking advantage of the fast-growing knowledge of the role of RBPs in the fine tuned post-transcriptional regulation of gene expression. We did not record a single or a few DRGs pointing to a specific gene pathway, but a network of DRGs, encoding defective RBPs connected by their shared roles in alternative splicing and ribosome biogenesis. Dysfunction resulting from the cumulative effect of multiple DRGs is specific to RSTS neurons, even if the cascade of events linking the mutated CREBBP/EP300 genes to the predicted defective RBP-ome profiling is currently unknown. Furthermore, the DRGs of this functionally coherent network encode interacting, often topologically associated, as well as “dual specificity” RBPs linking chromatin to the RBP-ome. This data gives a clue to the disentangling of the increasingly evident disease-associated perturbations of chromatin-RBP-ome cross-talk (Luco et al., 2010, 2011; Gonatopoulos-Pournatzis et al., 2018). The DRGs of RSTS iNeurons comprise genes dysregulated in known neurologic disorders including the recently recognized HNRNPH1-caused neurodevelopmental syndrome (Pilch et al., 2018; Reichert et al., 2020) which has a striking clinical overlap with Rubinstein-Taybi, possibly due to the numerous reciprocal interactions that deregulated RBPs engage forming RNPs with partially shared targetomes. The cross disorders marks, such as the presence, independent of mutations, of different RBPs sequestered in RNA foci in patients with neurodegenerative diseases, raise the challenge of discriminating their specific etiological contribution and enhance the development of therapeutic strategies with the potential to disrupt protein-RNA interfaces altered in disease states (Harrison and Shorter, 2017). As every RBP can control alternative splicing choices and may participate in interconnected pathways of ribonucleoprotein complex biogenesis, a high number of missplicing events is likely driven by the large set of downregulated RBPs in CBP/p300 defective iNeurons. Our transcriptome analysis focused on the differential expression of transcripts from annotated coding genes, while isoform level changes that capture the largest effects of diseased neurons (Gandal et al., 2018) were not addressed. A further layer of deleterious consequences, i.e. altered isoform expression, is predicted in RSTS iNeurons based on studies highlighting that CBP/p300 promotes the expression of the SRRM4 regulator, top hit of the highly conserved neuronal microexon splicing, deranged in Autism and psychiatric disorders (Gandal et al., 2018). Reduced CBP/p300 activity is not only at the roots of the rare Rubinstein-Taybi syndrome, but also implicated in several neurodegenerative conditions suggesting strategies for reinstatement of KAT activity based on epidrugs, such as histone deacetylase inhibitors (Valor et al., 2013). iPSC-derived cortical neurons from patients with diverse neurodegenerative diseases continue to provide insights into pathomechanisms underlying neurodegeneration and a platform for drug screening (Lines et al., 2020). The use of class I histone deacetylase inhibitors applied to forms of frontotemporal dementia caused by mutation of the GRN gene has been proposed as a promising therapeutic strategy to counteract the causative progranuline haploinsufficiency (She et al., 2017). Lastly, CBP and p300 are very large proteins that contain seven folded domains, but the regions outside these globular domains, accounting for about 60% of the sequence, are predicted to be intrinsically disordered and a disordered, autoinhibitory loop of ~60 residues is embedded in the KAT domain too (Dyson and Wright, 2016). The hub position of CBP/p300 in chromatin regulation is well attested by its huge interactome/acetylome (Bedford et al., 2010; Weinert et al., 2018). It remains to be seen whether CBP/p300 structural features, which resemble RBPs common features and pathomechanisms driving diseases with disrupted cognition, might account for a hub position of CBP/p300 in the RBP-ome.

1. Ajmone PF, Avignone S, Gervasini C, Giacobbe A, Monti F, Costantino A, Esposito S, Marchisio P, Triulzi F, Milani D. Rubinstein-Taybi syndrome: new neuroradiological and neuropsychiatric insights from a multidisciplinary approach Am J Med Genet B Neuropsychiatr Genet. 2018;177:406–415
2. Alarcon CR, Goodarzi H, Lee H, Liu X, Tavazoie S, Tavazoie SF. HNRNPA2B1 is a mediator of m(6)A-dependent nuclear RNA processing events Cell. 2015;162:1299–1308
3. Alari V, Russo S, Rovina D, Gowran A, Garzo M, Crippa M, Mazzanti L, Scalera C, Prosperi E, Giardino D, Gervasini C, Finelli P, Pompilio G, Larizza L. Generation of the Rubinstein-Taybi syndrome type 2 patient-derived induced pluripotent stem cell line (IAIi001-A) carrying the EP300 exon 23 stop mutation c.3829A>T, p(Lys1277*) Stem Cell Res. 2018a;30:175–179
    4. Alari V, Russo S, Terragni B, Ajmone PF, Sironi A, Catusi I, Calzari L, Concolino D, Marotta R, Milani D, Giardino D, Mantegazza M, Gervasini C, Finelli P, Larizza L. iPSC-derived neurons of CREBBP- and EP300-mutated Rubinstein-Taybi syndrome patients show morphological alterations and hypoexcitability Stem Cell Res. 2018b;30:130–140
      5. Alari V, Russo S, Rovina D, Garzo M, Crippa M, Calzari L, Scalera C, Concolino D, Castiglioni E, Giardino D, Prosperi E, Finelli P, Gervasini C, Gowran A, Larizza L. Generation of three iPSC lines (IAIi002, IAIi004, IAIi003) from Rubinstein-Taybi syndrome 1 patients carrying CREBBP non sense c. 4435G>T, p.(Gly1479*) and c.3474G>A, p(Trp1158*) and missense c4627G>T, p(Asp1543Tyr) mutations. Stem Cell Res 40:101553 2019
        6. Alfano L, Caporaso A, Altieri A, Dell’Aquila M, Landi C, Bini L, Pentimalli F, Giordano A. Depletion of the RNA binding protein HNRNPD impairs homologous recombination by inhibiting DNA-end resection and inducing R-loop accumulation Nucleic Acids Res. 2019;47:4068–4085
        7. Bain JM, Cho MT, Telegrafi A, Wilson A, Brooks S, Botti C, Gowans G, Autullo LA, Krishnamurthy V, Willing MC, Toler TL, Ben-Zev B, Elpeleg O, Shen Y, Retterer K, Monaghan KG, Chung WK. Variants in HNRNPH2 on the X chromosome are associated with a neurodevelopmental disorder in females Am J Hum Genet. 2016;99:728–734
        8. Bedford DC, Kasper LH, Fukuyama T, Brindle PK. Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases Epigenetics. 2010;5:9–15
        9. Benatar M, Wuu J, Fernandez C, Weihl CC, Katzen H, Steele J, Oskarsson B, Taylor JP. Motor neuron involvement in multisystem proteinopathy: implications for ALS Neurology. 2013;80:1874–1880
        10. Blazquez L, Emmett W, Faraway R, Pineda JMB, Bajew S, Gohr A, Haberman N, Sibley CR, Bradley RK, Irimia M, Ule J. Exon junction complex shapes the transcriptome by repressing recursive splicing Mol Cell. 2018;72:496–509
        11. Boehm V, Britto-Borges T, Steckelberg AL, Singh KK, Gerbracht JV, Gueney E, Blazquez L, Altmuller J, Dieterich C, Gehring NH. Exon junction complexes suppress spurious splice sites to safeguard transcriptome integrity Mol Cell. 2018;72:482–495
        12. Boisvert FM, van Koningsbruggen S, Navascues J, Lamond AI. The multifunctional nucleolus Nat Rev Mol Cell Biol. 2007;8:574–585
        13. Bonnet C, Andrieux J, Béri-Dexheimer M, Leheup B, Boute O, Manouvrier S, Delobel B, Copin H, Receveur A, Mathieu M, Thiriez G, Le Caignec C, David A, de Blois MC, Malan V, Philippe A, Cormier-Daire V, Colleaux L, Flori E, Dollfus H, et al Microdeletion at chromosome 4q21 defines a new emerging syndrome with marked growth restriction, mental retardation and absent or severely delayed speech J Med Genet. 2010;47:377–384
        14. Bono F, Ebert J, Lorentzen E, Conti E. The crystal structure of the exon junction complex reveals how it maintains a stable grip on mRNA Cell. 2006;126:713–725
        15. Bose DA, Berger SL. eRNA binding produces tailored CBP activity profiles to regulate gene expression RNA Biol. 2017;14:1655–1659
        16. Bramham CR, Wells DG. Dendritic mRNA: transport, translation and function Nat Rev Neurosci. 2007;8:776–789
        17. Brinegar AE, Cooper TA. Roles for RNA-binding proteins in development and disease Brain research. 2016;1647:1–8
        18. Cajigas IJ, Tushev G, Will TJ, tom Dieck S, Fuerst N, Schuman EM. The local transcriptome in the synaptic neuropil revealed by deep sequencing and high-resolution imaging Neuron. 2012;74:453–466
        19. Calzari L, Barcella M, Alari V, Braga D, Munoz-Viana R, Barlassina C, Finelli P, Gervasini C, Barco A, Russo S, Larizza L. Transcriptome analysis of iPSC-derived neurons from Rubinstein-Taybi patients reveals deficits in neuronal differentiation Mol Neurobiol. 2020;57:3685–3701
        20. Cervantes M, Forne I, Ranjit S, Gratton E, Imhof A, Sassone-Corsi P. BMAL1 associates with NOP58 in the nucleolus and contributes to pre-rRNA processing iScience. 2020;23:101151
          21. Chaudhury A, Chander P, Howe PH. Heterogeneous nuclear ribonucleoproteins (hnRNPs) in cellular processes: Focus on hnRNP E1’s multifunctional regulatory roles RNA. 2010;16:1449–1462
          22. Cooper-Knock J, Higginbottom A, Stopford MJ, Highley JR, Ince PG, Wharton SB, Pickering-Brown S, Kirby J, Hautbergue GM, Shaw PJ. Antisense RNA foci in the motor neurons of C9ORF72-ALS patients are associated with TDP-43 proteinopathy Acta Neuropathol. 2015;130:63–75
          23. Corley M, Burns MC, Yeo GW. How RNA-binding proteins interact with RNA: molecules and mechanisms Mol Cell. 2020;78:9–29
          24. Das U, Nguyen H, Xie J. Transcriptome protection by the expanded family of hnRNPs RNA Biol. 2019;16:155–159
          25. de Brouwer APM, Abou Jamra R, Körtel N, Soyris C, Polla DL, Safra M, Zisso A, Powell CA, Rebelo-Guiomar P, Dinges N, Morin V, Stock M, Hussain M, Shahzad M, Riazuddin S, Ahmed ZM, Pfundt R, Schwarz F, de Boer L, Reis A, et al Variants in PUS7 cause intellectual disability with speech delay, microcephaly, short stature, and aggressive behavior Am J Hum Genet. 2018;103:1045–1052
          26. DeRosa BA, El Hokayem J, Artimovich E, Garcia-Serje C, Phillips AW, Van Booven D, Nestor JE, Wang L, Cuccaro ML, Vance JM, Pericak-Vance MA, Cukier HN, Nestor MW, Dykxhoorn DM. Convergent pathways in idiopathic autism revealed by time course transcriptomic analysis of patient-derived neurons Sci Rep. 2018;8:8423
          27. Dyson HJ, Wright PE. Role of intrinsic protein disorder in the function and interactions of the transcriptional coactivators CREB-binding protein (CBP) and p300 J Biol Chem. 2016;291:6714–6722
          28. Fahrner JA, Bjornsson HT. Mendelian disorders of the epigenetic machinery: postnatal malleability and therapeutic prospects Hum Mol Genet. 2019;28:R254–R264
          29. Furlanis E, Scheiffele P. Regulation of neuronal differentiation, function, and plasticity by alternative splicing Annu Rev Cell Dev Biol. 2018;34:451–469
          30. Gandal MJ, Zhang P, Hadjimichael E, Walker RL, Chen C, Liu S, Won H, van Bakel H, Varghese M, Wang Y, Shieh AW, Haney J, Parhami S, Belmont J, Kim M, Moran Losada P, Khan Z, Mleczko J, Xia Y, Dai R, et al Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder Science. 2018;362:eaat8127
            31. Gerstberger S, Hafner M, Tuschl T. A census of human RNA-binding proteins Nat Rev Genet. 2014a;15:829–845
            32. Gerstberger S, Hafner M, Ascano M, Tuschl T. Evolutionary conservation and expression of human RNA-binding proteins and their role in human genetic disease Adv Exp Med Biol. 2014b;825:1–55
            33. Geuens T, Bouhy D, Timmerman V. The hnRNP family: insights into their role in health and disease Hum Genet. 2016;135:851–867
            34. Gonatopoulos-Pournatzis T, Blencowe BJ. Microexons: at the nexus of nervous system development, behaviour and autism spectrum disorder Curr Opin Genet Dev. 2020;65:22–33
            35. Gonatopoulos-Pournatzis T, Wu M, Braunschweig U, Roth J, Han H, Best AJ, Raj B, Aregger M, O’Hanlon D, Ellis JD, Calarco JA, Moffat J, Gingras AC, Blencowe BJ. Genome-wide CRISPR-Cas9 interrogation of splicing networks reveals a mechanism for recognition of autism-misregulated neuronal microexons Mol Cell. 2018;72:510–524.e512
            36. Grammatikakis I, Zhang P, Panda AC, Kim J, Maudsley S, Abdelmohsen K, Yang X, Martindale JL, Motino O, Hutchison ER, Mattson MP, Gorospe M. Alternative splicing of neuronal differentiation factor TRF2 regulated by HNRNPH1/H2 Cell Rep. 2016;15:926–934
              37. Gueroussov S, Weatheritt RJ, O’Hanlon D, Lin ZY, Narula A, Gingras AC, Blencowe BJ. Regulatory expansion in mammals of multivalent hnRNP assemblies that globally control alternative splicing Cell. 2017;170:324–339
              38. Guillen-Chable F, Corona UR, Pereira-Santana A, Bayona A, Rodriguez-Zapata LC, Aquino C, Sebestova L, Vitale N, Hozak P, Castano E. Fibrillarin ribonuclease activity is dependent on the GAR domain and modulated by phospholipids Cells. 2020;9:1143
                39. Han SP, Tang YH, Smith R. Functional diversity of the hnRNPs: past, present and perspectives Biochem J. 2010;430:379–392
                40. Harmsen S, Buchert R, Mayatepek E, Haack TB, Distelmaier F. Bain type of X-linked syndromic mental retardation in boys Clin Genet. 2019;95:734–735
                41. Harrison AF, Shorter J. RNA-binding proteins with prion-like domains in health and disease Biochem J. 2017;474:1417–1438
                42. Hennekam RC. Rubinstein-Taybi syndrome Eur J Hum Genet. 2006;14:981–985
                43. Hentze MW, Castello A, Schwarzl T, Preiss T. A brave new world of RNA-binding proteins Nat Rev Mol Cell Biol. 2018;19:327–341
                44. Hermann H, Fabrizio P, Raker VA, Foulaki K, Hornig H, Brahms H, Luhrmann R. snRNP Sm proteins share two evolutionarily conserved sequence motifs which are involved in Sm protein-protein interactions EMBO J. 1995;14:2076–2088
                45. Irimia M, Weatheritt RJ, Ellis JD, Parikshak NN, Gonatopoulos-Pournatzis T, Babor M, Quesnel-Vallieres M, Tapial J, Raj B, O’Hanlon D, Barrios-Rodiles M, Sternberg MJ, Cordes SP, Roth FP, Wrana JL, Geschwind DH, Blencowe BJ. A highly conserved program of neuronal microexons is misregulated in autistic brains Cell. 2014;159:1511–1523
                46. Jean-Philippe J, Paz S, Caputi M. hnRNP A1: the Swiss army knife of gene expression Int J Mol Sci. 2013;14:18999–19024
                47. Jepsen WM, Ramsey K, Szelinger S, Llaci L, Balak C, Belnap N, Bilagody C, De Both M, Gupta R, Naymik M, Pandey R, Piras IS, Sanchez-Castillo M, Rangasamy S, Narayanan V, Huentelman MJ. Two additional males with X-linked, syndromic mental retardation carry de novo mutations in HNRNPH2 Clin Genet. 2019;96:183–185
                48. Johnson WL, Yewdell WT, Bell JC, McNulty SM, Duda Z, O’Neill RJ, Sullivan BA, Straight AF. RNA-dependent stabilization of SUV39H1 at constitutive heterochromatin Elife. 2017;6:e25299
                  49. Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, MacLea KS, Freibaum B, Li S, Molliex A, Kanagaraj AP, Carter R, Boylan KB, Wojtas AM, Rademakers R, Pinkus JL, Greenberg SA, Trojanowski JQ, Traynor BJ, Smith BN, et al Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS Nature. 2013;495:467–473
                  50. Larizza L, Finelli P. Developmental disorders with intellectual disability driven by chromatin dysregulation: Clinical overlaps and molecular mechanisms Clin Genet. 2019;95:231–240
                  51. Levengood JD, Tolbert BS. Idiosyncrasies of hnRNP A1-RNA recognition: Can binding mode influence function Semin Cell Dev Biol. 2019;86:150–161
                  52. Li X, Fu XD. Chromatin-associated RNAs as facilitators of functional genomic interactions Nat Rev Genet. 2019;20:503–519
                  53. Lines G, Casey JM, Preza E, Wray S. Modelling frontotemporal dementia using patient-derived induced pluripotent stem cells Mol Cell Neurosci. 2020;109:103553
                  54. Lipscombe D, Lopez Soto EJ. Alternative splicing of neuronal genes: new mechanisms and new therapies Curr Opin Neurobiol. 2019;57:26–31
                  55. Liu N, Zhou KI, Parisien M, Dai Q, Diatchenko L, Pan T. N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein Nucleic Acids Res. 2017;45:6051–6063
                  56. Liu Y, Shi SL. The roles of hnRNP A2/B1 in RNA biology and disease Wiley Interdiscip Rev RNA. 2020:e1612
                    57. Lopez Soto EJ, Gandal MJ, Gonatopoulos-Pournatzis T, Heller EA, Luo D, Zheng S. Mechanisms of neuronal alternative splicing and strategies for therapeutic interventions J Neurosci. 2019;39:8193–8199
                    58. Luco RF, Allo M, Schor IE, Kornblihtt AR, Misteli T. Epigenetics in alternative pre-mRNA splicing Cell. 2011;144:16–26
                    59. Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, Misteli T. Regulation of alternative splicing by histone modifications Science. 2010;327:996–1000
                    60. Lukong KE, Chang KW, Khandjian EW, Richard S. RNA-binding proteins in human genetic disease Trends Genet. 2008;24:416–425
                    61. Lykke-Andersen S, Jensen TH. Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes Nat Rev Mol Cell Biol. 2015;16:665–677
                    62. Mathlin J, Le Pera L, Colombo T. A census and categorization method of epitranscriptomic marks Int J Mol Sc. 2020;21:4684
                      63. McMahon JJ, Shi L, Silver DL. Generation of a Magoh conditional allele in mice Genesis. 2014;52:752–758
                      64. Mills JA, Herrera PS, Kaur M, Leo L, McEldrew D, Tintos-Hernandez JA, Rajagopalan R, Gagne A, Zhang Z, Ortiz-Gonzalez XR, Krantz ID. NIPBL(+/-) haploinsufficiency reveals a constellation of transcriptome disruptions in the pluripotent and cardiac states Sci Rep. 2018;8:1056
                      65. Neelamraju Y, Hashemikhabir S, Janga SC. The human RBPome: from genes and proteins to human disease J Proteomics. 2015;127:61–70
                      66. Nussbacher JK, Tabet R, Yeo GW, Lagier-Tourenne C. Disruption of RNA metabolism in neurological diseases and emerging therapeutic interventions Neuron. 2019;102:294–320
                      67. Ojha S, Malla S, Lyons SM. snoRNPs: Functions in ribosome biogenesis Biomolecules. 2020;10:783
                        68. Peron A, Novara F, La Briola F, Merati E, Giannusa E, Segalini E, Anniballi G, Vignoli A, Ciccone R, Canevini MP. Missense variants in the Arg206 residue of HNRNPH2: further evidence of causality and expansion of the phenotype Am J Med Genet A. 2020;182:823–828
                        69. Picchiarelli G, Dupuis L. Role of RNA binding proteins with prion-like domains in muscle and neuromuscular diseases Cell Stress. 2020;4:76–91
                        70. Pilch J, Koppolu AA, Walczak A, Murcia Pienkowski VA, Biernacka A, Skiba P, Machnik-Broncel J, Gasperowicz P, Kosinska J, Rydzanicz M, Emich-Widera E, Ploski R. Evidence for HNRNPH1 being another gene for Bain type syndromic mental retardation Clinical genetics. 2018;94:381–385
                        71. Reichert SC, Li R, S AT, van Jaarsveld RH, Massink MPG, van den Boogaard MH, Del Toro M, Rodriguez-Palmero A, Fourcade S, Schluter A, Planas-Serra L, Pujol A, Iascone M, Maitz S, Loong L, Stewart H, De Franco E, Ellard S, Frank J, Lewandowski R. HNRNPH1-related syndromic intellectual disability: Seven additional cases suggestive of a distinct syndromic neurodevelopmental syndrome Clin Genet. 2020;98:91–98
                        72. Roake CM, Artandi SE. Regulation of human telomerase in homeostasis and disease Nat Rev Mol Cell Biol. 2020;21:384–397
                        73. Shashi V, Xie P, Schoch K, Goldstein DB, Howard TD, Berry MN, Schwartz CE, Cronin K, Sliwa S, Allen A, Need AC. The RBMX gene as a candidate for the Shashi X-linked intellectual disability syndrome Clin Genet. 2015;88:386–390
                        74. She A, Kurtser I, Reis SA, Hennig K, Lai J, Lang A, Zhao WN, Mazitschek R, Dickerson BC, Herz J, Haggarty SJ. Selectivity and kinetic requirements of HDAC inhibitors as progranulin enhancers for treating frontotemporal dementia Cell Chem Biol. 2017;24:892–906
                        75. Sheikh BN, Akhtar A. The many lives of KATs - detectors, integrators and modulators of the cellular environment Nat Rev Genet. 2019;20:7–23
                        76. Shishkin SS, Kovalev LI, Pashintseva NV, Kovaleva MA, Lisitskaya K. Heterogeneous nuclear ribonucleoproteins involved in the functioning of telomeres in malignant cells Int J Mol Sci. 2019;20:745
                        77. Singh KK, Wachsmuth L, Kulozik AE, Gehring NH. Two mammalian MAGOH genes contribute to exon junction complex composition and nonsense-mediated decay RNA Biol. 2013;10:1291–1298
                        78. Sloan KE, Warda AS, Sharma S, Entian KD, Lafontaine DLJ, Bohnsack MT. Tuning the ribosome: The influence of rRNA modification on eukaryotic ribosome biogenesis and function RNA Biol. 2017;14:1138–1152
                        79. Somashekar PH, Narayanan DL, Jagadeesh S, Suresh B, Vaishnavi RD, Bielas S, Girisha KM, Shukla A. Bain type of X-linked syndromic mental retardation in a male with a pathogenic variant in HNRNPH2 Am J Med Genet A. 2020;182:183–188
                        80. Sternburg EL, Karginov FV. Global approaches in studying RNA-binding protein interaction networks Trends Biochem Sci. 2020;45:593–603
                        81. Tessarz P, Santos-Rosa H, Robson SC, Sylvestersen KB, Nelson CJ, Nielsen ML, Kouzarides T. Glutamine methylation in histone H2A is an RNA-polymerase-I-dedicated modification Nature. 2014;505:564–568
                        82. Thelen MP, Kye MJ. The role of RNA binding proteins for local mRNA translation: implications in neurological disorders Front Mol Biosci. 2019;6:161
                          83. Valor LM, Viosca J, Lopez-Atalaya JP, Barco A. Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders Curr Pharm Des. 2013;19:5051–5064
                          84. Valor LM, Pulopulos MM, Jimenez-Minchan M, Olivares R, Lutz B, Barco A. Ablation of CBP in forebrain principal neurons causes modest memory and transcriptional defects and a dramatic reduction of histone acetylation but does not affect cell viability J Neurosci. 2011;31:1652–1663
                          85. van der Feltz C, Anthony K, Brilot A, Pomeranz Krummel DA. Architecture of the spliceosome Biochemistry. 2012;51:3321–3333
                          86. Velazquez Camacho O, Galan C, Swist-Rosowska K, Ching R, Gamalinda M, Karabiber F, De La Rosa-Velazquez I, Engist B, Koschorz B, Shukeir N, Onishi-Seebacher M, van de Nobelen S, Jenuwein T. Major satellite repeat RNA stabilize heterochromatin retention of Suv39h enzymes by RNA-nucleosome association and RNA:DNA hybrid formation Elife. 2017;6:e25293
                            87. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB. Alternative isoform regulation in human tissue transcriptomes Nature. 2008;456:470–476
                            88. Wang ET, Ward AJ, Cherone JM, Giudice J, Wang TT, Treacy DJ, Lambert NJ, Freese P, Saxena T, Cooper TA, Burge CB. Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins Genome Res. 2015;25:858–871
                            89. Wang L, Wen M, Cao X. Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to DNA viruses Science. 2019;365:eaav0758
                            90. Wang Y, Wang J, Gao L, Stamm S, Andreadis A. An SRp75/hnRNPG complex interacting with hnRNPE2 regulates the 5’ splice site of tau exon 10, whose misregulation causes frontotemporal dementia Gene. 2011;485:130–138
                            91. Watkins NJ, Bohnsack MT. The box C/D and H/ACA snoRNPs: key players in the modification, processing and the dynamic folding of ribosomal RNA Wiley Interdiscip Rev RNA. 2012;3:397–414
                              92. Weinert BT, Narita T, Satpathy S, Srinivasan B, Hansen BK, Scholz C, Hamilton WB, Zucconi BE, Wang WW, Liu WR, Brickman JM, Kesicki EA, Lai A, Bromberg KD, Cole PA, Choudhary C. Time-resolved analysis reveals rapid dynamics and broad scope of the CBP/p300 acetylome Cell. 2018;174:231–244
                              93. White EJ, Matsangos AE, Wilson GM. AUF1 regulation of coding and noncoding RNA Wiley Interdiscip Rev RNA. 2017;8 doi: 101002/wrna1393
                                94. Yamazaki T, Liu L, Lazarev D, Al-Zain A, Fomin V, Yeung PL, Chambers SM, Lu CW, Studer L, Manley JL. TCF3 alternative splicing controlled by hnRNP H/F regulates E-cadherin expression and hESC pluripotency Genes Dev. 2018;32:1161–1174
                                95. Zhang QS, Manche L, Xu RM, Krainer AR. hnRNP A1 associates with telomere ends and stimulates telomerase activity RNA. 2006;12:1116–1128

                                C-Editors: Zhao M, Zhao LJ, Qiu Y; T-Editor: Jia Y

                                Funding:This work was supported by Italian Ministery of Health RC 08C921 to LL, Istituto Auxologico Italiano, IRCCs.

                                Conflicts of interest:The authors declare no conflicts of interest.

                                Financial support:This work was supported by Italian Ministery of Health RC 08C921 to LL, Istituto Auxologico Italiano, IRCCs.

                                Copyright license agreement:The Copyright License Agreement has been signed by all authors before publication.

                                Plagiarism check:Checked twice by iThenticate.

                                Peer review:Externally peer reviewed.


                                alternative splicing; CBP/p300; chromatin regulators; downregulated genes; induced pluripotent stem cell-neurons; neurodevelopmental disorders; ribosome biogenesis; RNA-binding proteins; RNASeq; Rubinstein-Taybi

                                © 2022 Neural Regeneration Research | Published by Wolters Kluwer – Medknow